OneSource Specialty Pharma has informed that the company have received notice on May 29, 2025 from National Stock Exchange of India and BSE for non-compliance of Regulation 19 (1) /19(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) regarding composition of Nomination and Remuneration Committee for the quarter ended March 31, 2025. The Company has rectified the inadvertent error by re-constituting the NRC in line with the SEBI (LODR) requirement on May 09, 2025. The details as required under SEBI Listing Regulations read with Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024 are provided as an Annexure.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: